By P. R. Lichtlen (auth.), Professor Dr. P. R. Lichtlen, Professor Dr. A. Reale (eds.)
As little as 30 years in the past, cardiovascular learn at Bayer used to be only a small sideline with in an atmosphere ruled by means of chemotherapy study, and in simple terms 15 years in the past, Bayer's pharmaceutical company was once restricted to eu and Latin Ameri can nations, with revenues in cardiovascular prescribed drugs on the subject of 0. It is going with no asserting that Adalat has replaced the corporate as an entire in its learn, improvement, and advertising, either in Germany and, most significantly, international broad. In learn and improvement, Adalat has led the best way in to new parts reminiscent of high blood pressure, acute neurology, dementia, atherosclerosis, and center failure. In pharmacology, Adalat used to be current on the dawning of the second one phar macological revolution, which began from complete animal versions and progres sed, through in vitro screening and pharmacological examine at the DHP receptor, all the way down to the molecular point with the cloning of calcium-channel proteins. Having the Adalat tale heavily in its early years as a bench scientist, allow me take this chance to thank the inventors, the scientists, and the investigators who've helped to faucet the huge power of calcium-channel blockade with dihyd ropyridines typically and Adalat particularly. yet, good fortune usually are not imprecise our imaginative and prescient. there's no explanation for us to leisure on our laurels: it's going to take precise concepts in cardiovascular study to most sensible the most appropriate set by way of Adalat. allow us to take in the challenge.
Read or Download Adalat: A Comprehensive Review PDF
Best nonfiction_11 books
- Relativistic and Electron Correlation Effects in Molecules and Solids
- Scale Models in Engineering. Fundamentals and Applications
- Retrial Queues
- Aircraft Profile No. 16: The Fiat CR.42
Additional info for Adalat: A Comprehensive Review
The first job was to present the new ideas on pathophysiology skillfully and clearly so that this theoretical advance would be reflected in actual prescribing-habits. This meant that Bayer Marketing first had to get to know the cardiovascular scene in depth, a field in which the company had scarcely been involved until then. In other words, cardiovascular marketing practically had to start from scratch, working in the researchers to give the product a profile in the company and in clinical practice.
One hypothesis includes calcium overload as one of these factors. In later experi- 20 S. Kazda Fig. 7. Histological feature of healing of malignant hypertensive arteriopathy in the mesentery of a Dahl S-rat after 6-week treatment with nifedipine. Intimal fibrin resorption has taken place, supporting reendothelization. An additional elastic lamina has formed on the luminal side of the original internal elastic lamina  ments with other rat strains (stroke-prone spontaneously hypertensive rats, SHR) and with another dihydropyridine derivative, nimodipine, which has only a weak effect on peripheral vessels, we confirmed this hypothesis and extended its validity to other pathological states such as experimental stroke .
Only later, however, was it realized that the relieving effect on the diseased heart and associated reduction in oxygen-consumption resulted specifically from a reduction in afterload, i. , a shift from pressure work to volume work. Eventually, before the 1960s were out, Professor Albert Fleckenstein discovered the biochemical mechanism; thus the term calcium antagonist for nifedipine was born, and the high vasorelaxant potency of the substance was found to explain its clinical efficacy. Calcium antagonism, as a newly discovered therapeutic quality in the treatment of cardiovascular diseases, also inspired marketing.
Adalat: A Comprehensive Review by P. R. Lichtlen (auth.), Professor Dr. P. R. Lichtlen, Professor Dr. A. Reale (eds.)